NO329616B1 - Anvendelse av treosulfan for fremstilling av et farmasøytisk preparat til bruk i forbindelse med allogen transplantasjon av benmarg eller hematopoetiske stamceller - Google Patents

Anvendelse av treosulfan for fremstilling av et farmasøytisk preparat til bruk i forbindelse med allogen transplantasjon av benmarg eller hematopoetiske stamceller Download PDF

Info

Publication number
NO329616B1
NO329616B1 NO20022109A NO20022109A NO329616B1 NO 329616 B1 NO329616 B1 NO 329616B1 NO 20022109 A NO20022109 A NO 20022109A NO 20022109 A NO20022109 A NO 20022109A NO 329616 B1 NO329616 B1 NO 329616B1
Authority
NO
Norway
Prior art keywords
use according
treosulfan
conditioning
days
surface area
Prior art date
Application number
NO20022109A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022109L (no
NO20022109D0 (no
Inventor
Joachim Baumgart
Original Assignee
Medac Klinische Spezialpraep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medac Klinische Spezialpraep filed Critical Medac Klinische Spezialpraep
Publication of NO20022109D0 publication Critical patent/NO20022109D0/no
Publication of NO20022109L publication Critical patent/NO20022109L/no
Publication of NO329616B1 publication Critical patent/NO329616B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
NO20022109A 1999-11-05 2002-05-02 Anvendelse av treosulfan for fremstilling av et farmasøytisk preparat til bruk i forbindelse med allogen transplantasjon av benmarg eller hematopoetiske stamceller NO329616B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953517A DE19953517C1 (de) 1999-11-05 1999-11-05 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation
PCT/EP2000/010871 WO2001032154A2 (de) 1999-11-05 2000-11-03 Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation

Publications (3)

Publication Number Publication Date
NO20022109D0 NO20022109D0 (no) 2002-05-02
NO20022109L NO20022109L (no) 2002-07-01
NO329616B1 true NO329616B1 (no) 2010-11-22

Family

ID=7928187

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20022109A NO329616B1 (no) 1999-11-05 2002-05-02 Anvendelse av treosulfan for fremstilling av et farmasøytisk preparat til bruk i forbindelse med allogen transplantasjon av benmarg eller hematopoetiske stamceller
NO2019032C NO2019032I1 (no) 1999-11-05 2019-07-23 Treosulfan

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2019032C NO2019032I1 (no) 1999-11-05 2019-07-23 Treosulfan

Country Status (16)

Country Link
US (1) US7199162B1 (cg-RX-API-DMAC7.html)
EP (1) EP1227808B1 (cg-RX-API-DMAC7.html)
JP (1) JP4846151B2 (cg-RX-API-DMAC7.html)
AT (1) ATE251455T1 (cg-RX-API-DMAC7.html)
AU (1) AU777527B2 (cg-RX-API-DMAC7.html)
BG (1) BG65845B1 (cg-RX-API-DMAC7.html)
CA (1) CA2389896C (cg-RX-API-DMAC7.html)
CZ (1) CZ299701B6 (cg-RX-API-DMAC7.html)
DE (2) DE19953517C1 (cg-RX-API-DMAC7.html)
EA (1) EA004543B1 (cg-RX-API-DMAC7.html)
ES (1) ES2208435T3 (cg-RX-API-DMAC7.html)
HU (2) HU227332B1 (cg-RX-API-DMAC7.html)
NO (2) NO329616B1 (cg-RX-API-DMAC7.html)
PL (1) PL212132B1 (cg-RX-API-DMAC7.html)
UA (1) UA73961C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001032154A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP7431815B2 (ja) * 2018-09-26 2024-02-15 メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク トレオスルファンの結晶形
PT4257122T (pt) 2018-09-26 2026-06-08 Medac Ges Fr Klinische Spezialprparate Mbh Liofilizado de treossulfano
EP3856252A1 (en) 2018-09-26 2021-08-04 medac Gesellschaft für klinische Spezialpräparate mbH Solution comprising treosulfan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting

Also Published As

Publication number Publication date
CA2389896A1 (en) 2001-05-10
ATE251455T1 (de) 2003-10-15
CZ20021562A3 (cs) 2002-10-16
BG65845B1 (bg) 2010-03-31
EP1227808B1 (de) 2003-10-08
NO2019032I1 (no) 2019-07-23
DE50004024D1 (de) 2003-11-13
EP1227808A2 (de) 2002-08-07
CZ299701B6 (cs) 2008-10-22
AU1391801A (en) 2001-05-14
WO2001032154A2 (de) 2001-05-10
DE19953517C1 (de) 2001-08-09
NO20022109L (no) 2002-07-01
US7199162B1 (en) 2007-04-03
PL212132B1 (pl) 2012-08-31
ES2208435T3 (es) 2004-06-16
EA004543B1 (ru) 2004-06-24
AU777527B2 (en) 2004-10-21
HUP0203277A2 (en) 2003-01-28
PL356240A1 (en) 2004-06-28
BG106772A (bg) 2003-02-28
NO20022109D0 (no) 2002-05-02
CA2389896C (en) 2007-04-10
UA73961C2 (uk) 2005-10-17
WO2001032154A3 (de) 2002-01-24
JP2003513034A (ja) 2003-04-08
JP4846151B2 (ja) 2011-12-28
EA200200535A1 (ru) 2002-10-31
HU227332B1 (en) 2011-03-28
HUS1900041I1 (hu) 2019-10-28

Similar Documents

Publication Publication Date Title
AU675092B2 (en) Methods of combating (pneumocystis carinii) pneumonia and compounds useful therefor
US6051596A (en) Immunosuppressive compositions
Takvorian et al. Autologous bone-marrow transplantation: host effects of high-dose BCNU.
TW466112B (en) Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
EP4126905A1 (en) Cyclophilin inhibitors and uses thereof
KR100834138B1 (ko) 카할라리드 에프
AU2018212530B2 (en) Fecal microbiota for treating patients undergoing a hematopoietic stem cell transplant
JPH04505760A (ja) Aztの副作用および毒性からの保護方法
Vasanthan et al. Periodontal treatment considerations for cell transplant and organ transplant patients.
Gorin et al. High dose combination chemotherapy (TACC) with and without autologous bone marrow transplantation for the treatment of acute leukaemia and other malignant diseases: Kinetics of recovery of haemopoiesis. A preliminary study of 12 cases
CN100479814C (zh) 促淋巴细胞归巢剂在制备用于治疗移植物功能恢复延迟的药物中的用途
MC1575A1 (fr) Nouveau derives de la guanine
US7199162B1 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
Uber et al. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications
EP0081882A1 (en) Medicine having transplant rejection and/or immunological inflammation inhibiting activities, as well as a method for inhibiting transplant rejection and/or immunological inflammation
US3683070A (en) Antihypertensive compositions
JPH1112170A (ja) グリシン含有医療用組成物
WO2000043403A1 (en) 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
Humes et al. Acute renal failure and toxic nephropathy
Bajaj et al. Insulin antagonism of normal and diabetic albumin after liver perfusion
Khashimova et al. A study of the mechanism of the action of extensin-like proteins of the cotton plant in a cell culture
CZ20003772A3 (cs) Farmaceutický prostředek s imunosupresivním účinkem a jeho použití
JPH08771B2 (ja) 血行阻害による酸素の供給低下及び再灌流による酸素の再供給に起因する臓器の機能低下改善剤
Marchetti et al. Long‐term survival of pig‐to‐mouse Islet xenografts
JPH04327541A (ja) 拒絶反応による移植臓器障害治療剤

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: TREOSULFAN; REG. NO/DATE: EU/1/18/1351 20190620

Spc suppl protection certif: 2019032

Filing date: 20190723

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEP, DE

MK1K Patent expired